The intervention involves administering ceralasertib, an experimental drug, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily for a week, while the other drugs are administered in single ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Pamplona will pay $88.10 per share in cash for Parexel, representing a 5 percent premium to the stock's Monday close. Parexel's shares were trading at $87.67 before the bell, just shy of the offer ...

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications ...

Parexel was founded in 1982 and is led by Jamie McDonald, who prior to his role at the CRO was a senior advisor to EQT. Parexel’s headcount is approximately 17,000.

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development. Parexel, a clinical research organization ...

Parexel’s commitment towards being a diverse organization that builds on its employees’ skills to deliver groundbreaking work is considered to be one of the greatest motivations for employees ...

PAREXEL has overcome this by creating a knowledge repository called SIMS (Site Intelligence Management System) that collects data on investigator performance from numerous different sources.

25-year industry veteran and Biotech business leader recognized among the most inspiring people in life sciencesBOSTON and DURHAM, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading ...

For the full fiscal year, Parexel cranked out $1.7 billion in revenue, a 24% jump over 2012, and, thanks to its recent acquisitions and expanding market share, the CRO is expecting up to $1.9 ...

Parexel, which conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process, has been an IFS customer for the past 15 years.

Parexel, the Newton-based company that helps run clinical trials for the pharmaceutical industry, said Friday it would be bought by the Swedish private equity firm EQT and Goldman Sachs Asset ...